EHRA Premium Access

Is there still room for drugs to control atrioventricular nodal conduction in atrial fibrillation (AF)?

Event: EHRA 2022
Topic: Atrial Fibrillation (AF)
Session type: Symposium
Date: 5 April 2022
Time: 08:30 - 09:30

Congress Session

Become an EHRA member to access this resource

Become a member

Already a member? Sign in

5 presentations in this session

AV nodal blocking therapy in AF: when, how and for whom?

Speaker: Associate Professor S. Boveda (Toulouse, FR)
Thumbnail

The role of digoxin in atrial fibrillation.

Speaker: Professor P. Kirchhof (Hamburg, DE)
Thumbnail

The role of a calcium channel blocker in atrial fibrillation.

Speaker: Doctor R. Tieleman (Groningen, NL)
Thumbnail

Ablate and pace: the preferred therapy now?

Speaker: Professor P. Vardas (Heraklion, GR)
Thumbnail

Is there still room for drugs to control AV nodal conduction in AF? - discussion.

Thumbnail

4 speakers from this session

Associate Professor Serge Boveda

Clinic Pasteur, Toulouse (France)
15 presentations
3 followers

Professor Paulus Kirchhof

University Heart & Vascular Center UKE Hamburg, Hamburg (Germany)
43 presentations
2 followers

Doctor Robert Tieleman

Martini Hospital, Groningen (Netherlands (The))
1 presentation
0 follower

Professor Panagiotis Vardas

University Hospital of Heraklion, Heraklion (Greece)
15 presentations
1 follower

Related content

ESC Premium Access

Trials Focus: APAF-CRT / ACST-2

4 December 2021

ESC Premium Access

ESC Guidelines 2021 - Heart Failure

3 December 2021

ESC Premium Access

Update on endocarditis in 2021

3 December 2021

This platform is supported by

logo Novo Nordisk